Clinical Trial Update: A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety of risankizumab in psoriatic arthritis patients who completed Week 24 of a prior study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriatic Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2019-05-28